Institute for Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Institute for Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-140,000,000	Closed	-$14K	–	493
2019 Q1	$14K	Buy	+140,000,000	New	+$2.47B	﹤0.01%	448

Other funds holding TEVA

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

TAM

Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

YDMI

Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Institute for Wealth Management's TEVA Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 108 shares worth $3.66K. The stake represents ﹤0.01% of the portfolio and ranks #1505 among its holdings. This is a return to the name: Institute for Wealth Management previously reported a position in TEVA as recently as Q2 2022.

Institute for Wealth Management first reported a position in TEVA in Q1 2019 and has held it in 4 quarters since. The position peaked at $293K in Q2 2022. 310 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Institute for Wealth Management held 108 shares of Teva Pharmaceuticals worth $3.66K as of Q2 2026.
Teva Pharmaceuticals was a new Institute for Wealth Management position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1505 holding.
Institute for Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
Institute for Wealth Management's Teva Pharmaceuticals position peaked at $293K in Q2 2022.
310 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.